Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab With or Without Docetaxel in Previously Treated Metastatic Pancreatic Adenocarcinoma
NCT00066677Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Oct 2003
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in pancreatic adenocarcinoma (PDAC), sponsored by Fox Chase Cancer Center. Started Oct 2003; status: terminated.
02
Drugs
bevacizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00066677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00066677.